Name of opportunity: 👀
AstraZeneca Corp
FDA approved drug 💊
AstraZeneca Corp is up by 1.30% over the past day, this might be because its Infiminzi drug was recently approved to treat bladder cancer in the U.S. Imfinzi is the brand name for Durvalumab, which is an anti-cancer drug developed by Medimmune/AstraZeneca.
AstraZeneca is currently said to be performing well, with strong revenue, cash flow, and profits, which supports its growth potential.
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of AstraZeneca PLC might increase from $73.79 to $86.36 in the next 12 months. If you invested $1000, you might profit $170.38.
Infimzi in combination with other drugs has been approved by the FDA to treat bladder cancer. This treatment will be available for adult patients with muscle-invasive bladder cancer (MIBC) This is positive news, as FDA approval for this treatment has expanded the treatment options for bladder cancer patients. In the U.S, over 20,000 were treated for MIBC, this treatment may provide life-changing care for many people. This might also bring positive sentiment to AstraZeneca.
FDA approval might also mean potential revenue increase for AstraZeneca, this kind of news might attract investor attention. Potential growth might drive the stock price of a company up, due to investor confidence within the company. Could now be a good time to invest in AstraZeneca? Analysts are calling this stock a ‘buy’ right now—almost a strong buy!
Biotechnology 🧫
AstraZeneca plc is a British-Swedish multinational pharmaceutical company. The company is headquartered in Cambridge, United Kingdom, in the Cambridge Biomedical Campus.
Which neme?: 🔍
‘Made in the UK’, ‘Pharma’
Download Nemo Money to check out AstraZeneca. New users can grab our registration bonus up to a maximum of $50 on first deposit. Terms and conditions apply.
